Emerald Health Therapeutics (CVE:EMH) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.
Profitability
This table compares Emerald Health Therapeutics and Hemostemix's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Emerald Health Therapeutics | N/A | N/A | N/A |
Hemostemix | N/A | N/A | N/A |
Valuation & Earnings
This table compares Emerald Health Therapeutics and Hemostemix's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Emerald Health Therapeutics | C$13.02 million | 4.17 | C$-142,699,488.00 | C($0.70) | -0.38 |
Hemostemix | N/A | N/A | N/A | C($0.17) | -2.86 |
Hemostemix has lower revenue, but higher earnings than Emerald Health Therapeutics. Hemostemix is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Emerald Health Therapeutics and Hemostemix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Emerald Health Therapeutics | 0 | 0 | 0 | 0 | N/A |
Hemostemix | 0 | 0 | 0 | 0 | N/A |
Summary
Emerald Health Therapeutics beats Hemostemix on 2 of the 3 factors compared between the two stocks.